Literature DB >> 28667482

Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS.

Yaou Liu1,2,3,4, Yunyun Duan5, Jing Huang5, Zhuoqiong Ren5, Zheng Liu6, Huiqing Dong6, Florian Weiler7, Horst K Hahn7, Fu-Dong Shi8, Helmut Butzkueven9, Frederik Barkhof10,11, Kuncheng Li12,13.   

Abstract

OBJECTIVE: To investigate the longitudinal spinal cord and brain changes in neuromyelitis optica (NMO) and multiple sclerosis (MS) and their associations with disability progression. PATIENTS AND METHODS: We recruited 28 NMO, 22 MS, and 20 healthy controls (HC), who underwent both spinal cord and brain MRI at baseline. Twenty-five NMO and 20 MS completed 1-year follow-up. Baseline spinal cord and brain lesion loads, mean upper cervical cord area (MUCCA), brain, and thalamus volume and their changes during a 1-year follow-up were measured and compared between groups. All the measurements were also compared between progressive and non-progressive groups in NMO and MS.
RESULTS: MUCCA decreased significantly during the 1-year follow-up in NMO not in MS. Percentage brain volume changes (PBVC) and thalamus volume changes in MS were significantly higher than NMO. MUCCA changes were significantly different between progressive and non-progressive groups in NMO, while baseline brain lesion volume and PBVC were associated with disability progression in MS. MUCCA changes during 1-year follow-up showed association with clinical disability in NMO.
CONCLUSION: Spinal cord atrophy changes were associated with disability progression in NMO, while baseline brain lesion load and whole brain atrophy changes were related to disability progression in MS. KEY POINTS: • Spinal cord atrophy progression was observed in NMO. • Spinal cord atrophy changes were associated with disability progression in NMO. • Brain lesion and atrophy were related to disability progression in MS.

Entities:  

Keywords:  Brain; MRI; Mean upper cervical cord area; Multiple sclerosis; Neuromyelitis optica

Mesh:

Year:  2017        PMID: 28667482     DOI: 10.1007/s00330-017-4921-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  35 in total

1.  Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.

Authors:  Ju-Hong Min; Byoung Joon Kim; Kwang Ho Lee
Journal:  Mult Scler       Date:  2011-12-06       Impact factor: 6.312

Review 2.  Advances in functional and structural MR image analysis and implementation as FSL.

Authors:  Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews
Journal:  Neuroimage       Date:  2004       Impact factor: 6.556

3.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

Authors:  D H Miller; F Barkhof; I Berry; L Kappos; G Scotti; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

4.  Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica.

Authors:  Toshiyuki Takahashi; Kazuo Fujihara; Ichiro Nakashima; Tatsuro Misu; Isabelle Miyazawa; Masashi Nakamura; Shohei Watanabe; Naoto Ishii; Yasuto Itoyama
Journal:  Tohoku J Exp Med       Date:  2006-12       Impact factor: 1.848

5.  No MRI evidence of cortical lesions in neuromyelitis optica.

Authors:  Massimiliano Calabrese; Mi Sun Oh; Alice Favaretto; Francesca Rinaldi; Valentina Poretto; Sara Alessio; Byung-Chul Lee; Kyung-Ho Yu; Hyeo-Il Ma; Paola Perini; Paolo Gallo
Journal:  Neurology       Date:  2012-09-19       Impact factor: 9.910

6.  Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis.

Authors:  Menno M Schoonheim; Hanneke E Hulst; Roemer B Brandt; Myrte Strik; Alle Meije Wink; Bernard M J Uitdehaag; Frederik Barkhof; Jeroen J G Geurts
Journal:  Neurology       Date:  2015-01-23       Impact factor: 9.910

7.  Cervical cord FMRI abnormalities differ between the progressive forms of multiple sclerosis.

Authors:  Paola Valsasina; Maria A Rocca; Martina Absinta; Federica Agosta; Domenico Caputo; Giancarlo Comi; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2011-08-25       Impact factor: 5.038

Review 8.  The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Yong Guo; Bogdan F Gh Popescu; Kazuo Fujihara; Yasuto Itoyama; Tatsuro Misu
Journal:  Brain Pathol       Date:  2014-01       Impact factor: 6.508

9.  Validation of the automated method VIENA: an accurate, precise, and robust measure of ventricular enlargement.

Authors:  Hugo Vrenken; Eline K Vos; W M van der Flier; Ingrid C Sluimer; Keith S Cover; Dirk L Knol; Frederik Barkhof
Journal:  Hum Brain Mapp       Date:  2013-01-30       Impact factor: 5.038

Review 10.  Magnetic resonance imaging in neuromyelitis optica.

Authors:  George Tackley; Wilhelm Kuker; Jacqueline Palace
Journal:  Mult Scler       Date:  2014-05-14       Impact factor: 6.312

View more
  7 in total

1.  Longitudinal ultra-high field MRI of brain lesions in neuromyelitis optica spectrum disorders.

Authors:  Sanjeev Chawla; Yulin Ge; Jens Wuerfel; Shadi Asadollahi; Suyash Mohan; Friedemann Paul; Tim Sinnecker; Ilya Kister
Journal:  Mult Scler Relat Disord       Date:  2020-03-25       Impact factor: 4.339

2.  Structural-visual functional relationships detected by optical coherence tomography in varying age-cohorts' patients with optic neuritis.

Authors:  Wei Shi; Hong-Tao Zhang; Hua-Xin Zuo; Si-Yuan Li; Pan-Pan Zheng; Quan-Gang Xu; Si-Yu Cai; Shi-Hui Wei; Li Li; Chun-Xia Peng
Journal:  Int J Ophthalmol       Date:  2022-06-18       Impact factor: 1.645

3.  Study on the Anti-demyelination Mechanism of Bu-Shen-Yi-Sui Capsule in the Central Nervous System Based on Network Pharmacology and Experimental Verification.

Authors:  Zheng Zha; Yi-Jiang Liu; Si-Si Liu; Nan Zhang; Jun-Ling Li; Fang Qi; Liang-Yun Jin; Bing Xue; Tao Yang; Yong-Ping Fan; Hui Zhao; Lei Wang
Journal:  Mediators Inflamm       Date:  2022-07-12       Impact factor: 4.529

4.  Repeatability and reproducibility of FreeSurfer, FSL-SIENAX and SPM brain volumetric measurements and the effect of lesion filling in multiple sclerosis.

Authors:  Chunjie Guo; Daniel Ferreira; Katarina Fink; Eric Westman; Tobias Granberg
Journal:  Eur Radiol       Date:  2018-09-21       Impact factor: 5.315

5.  Changes in mitochondrial function in patients with neuromyelitis optica; correlations with motor and cognitive disabilities.

Authors:  Forough Foolad; Fariba Khodagholi; Seyed Massood Nabavi; Mohammad Javan
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

6.  Quantitative Magnetic Resonance Imaging Analysis of Early Markers of Upper Cervical Cord Atrophy in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.

Authors:  Iman Adibi; Afshin Najafi; Fouad Merajifar; Neda Ramezani; Hosein Nouri; Nassim Jalilvand; Fereshteh Ashtari; Alireza Vard; Vahid Shaygannejad
Journal:  Mult Scler Int       Date:  2021-07-09

7.  Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.

Authors:  Hiroki Masuda; Masahiro Mori; Shigeki Hirano; Akiyuki Uzawa; Tomohiko Uchida; Mayumi Muto; Ryohei Ohtani; Reiji Aoki; Satoshi Kuwabara
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-08-06       Impact factor: 10.154

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.